Actinium Pharmaceuticals, Inc.

Symbol: ATNM

AMEX

8.75

USD

Market price today

  • -5.3430

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 260.61M

    MRK Cap

  • 0.00%

    DIV Yield

Actinium Pharmaceuticals, Inc. (ATNM) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

-9.17%

Operating Profit Margin

-616.46%

Net Profit Margin

-573.47%

Return on Assets

-0.53%

Return on Equity

-1.05%

Return on Capital Employed

-0.62%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Sandesh C. Seth M.B.A., M.S.
Full-time employees:49
City:New York
Address:275 Madison Avenue
IPO:2012-12-27
CIK:0001388320

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

General Outlook

When we look at how much money they make before expenses, they keep -9.173% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -616.457%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -573.469%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.526% return, is a testament to Actinium Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Actinium Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.050%. Furthermore, the proficiency of Actinium Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.622% return on capital employed.

Stock Prices

Actinium Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $7.96, while its low point bottomed out at $7.61. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Actinium Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing ATNM liquidity ratios reveals its financial health of the firm. The current ratio of 1058.69% gauges short-term asset coverage for liabilities. The quick ratio (1042.37%) assesses immediate liquidity, while the cash ratio (1042.37%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio1058.69%
Quick Ratio1042.37%
Cash Ratio1042.37%

Profitability Ratios

ATNM profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -57346.91% underscores its earnings before tax deductions. The effective tax rate stands at -1.18%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 93.03%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -61645.68%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-57346.91%
Effective Tax Rate-1.18%
Net Income per EBT100.00%
EBT per EBIT93.03%
EBIT per Revenue-61645.68%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 10.59, it details the span from stock purchase to revenue. The 10 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding1042
Days of Payables Outstanding3328
Cash Conversion Cycle-3328
Payables Turnover0.11
Fixed Asset Turnover0.03

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.42, and free cash flow per share, -1.42, depict cash generation on a per-share basis. The cash per share value, 3.01, showcases liquidity position. Lastly, the operating cash flow sales ratio, -489.28, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-1.42
Free Cash Flow per Share-1.42
Cash per Share3.01
Operating Cash Flow Sales Ratio-489.28
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-20.00
Short Term Coverage Ratio-71.93
Capital Expenditure Coverage Ratio-450.36
Dividend Paid and Capex Coverage Ratio-450.36

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.24%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.05, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.16%, and total debt to capitalization, 4.32%, ratios shed light on its capital structure. An interest coverage of -91.29 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.24%
Debt Equity Ratio0.05
Long Term Debt to Capitalization3.16%
Total Debt to Capitalization4.32%
Interest Coverage-91.29
Cash Flow to Debt Ratio-20.00
Company Equity Multiplier2.01

Per Share Data

Net income per share, -1.83, reflects the portion of profit attributed to each share. The book value per share, 1.37, represents the net asset value distributed per share, while the tangible book value per share, 1.37, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-1.83
Book Value Per Share1.37
Tangible Book Value Per Share1.37
Shareholders Equity Per Share1.37
Interest Debt Per Share0.08
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -92.14%, indicates top-line expansion, while the gross profit growth, -314.20%, reveals profitability trends. EBIT growth, -52.24%, and operating income growth, -52.24%, offer insights into operational profitability progression. The net income growth, -52.89%, showcases bottom-line expansion, and the EPS growth, -38.64%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-92.14%
Gross Profit Growth-314.20%
EBIT Growth-52.24%
Operating Income Growth-52.24%
Net Income Growth-52.89%
EPS Growth-38.64%
EPS Diluted Growth-38.64%
Weighted Average Shares Growth10.20%
Weighted Average Shares Diluted Growth10.20%
Operating Cash Flow Growth-647.61%
Free Cash Flow Growth-673.67%
10-Year Operating CF Growth per Share78.56%
5-Year Operating CF Growth per Share69.43%
3-Year Operating CF Growth per Share0.13%
10-Year Net Income Growth per Share87.08%
5-Year Net Income Growth per Share72.58%
3-Year Net Income Growth per Share-1.04%
10-Year Shareholders Equity Growth per Share166.50%
5-Year Shareholders Equity Growth per Share-45.15%
3-Year Shareholders Equity Growth per Share-72.94%
Asset Growth-28.68%
Book Value per Share Growth-50.34%
Debt Growth-18.13%
R&D Expense Growth63.73%
SGA Expenses Growth11.10%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 60,584,548.6, captures the company's total value, considering both debt and equity. Income quality, 0.97, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 164.58, gauges operational efficiency, while the research and development to revenue, 46765.43%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value60,584,548.6
Income Quality0.97
Sales General and Administrative to Revenue164.58
Research and Development to Revenue46765.43%
Capex to Operating Cash Flow0.32%
Capex to Revenue-188.89%
Capex to Depreciation-19.37%
Stock-Based Compensation to Revenue4743.21%
Graham Number7.51
Return on Tangible Assets-59.94%
Graham Net Net1.19
Working Capital69,769,000
Tangible Asset Value36,379,000
Net Current Asset Value33,197,000
Average Payables9,041,500
Days Payables Outstanding3674
ROIC-134.89%
ROE-1.34%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.66, and the price to book ratio, 5.66, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3272.51, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -6.67, and price to operating cash flows, -6.26, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.66
Price to Book Ratio5.66
Price to Sales Ratio3272.51
Price Cash Flow Ratio-6.26
Enterprise Value Multiple-7.07
Price Fair Value5.66
Price to Operating Cash Flow Ratio-6.26
Price to Free Cash Flows Ratio-6.67
Price to Tangible Book Ratio3.72
Enterprise Value to Sales747.96
Enterprise Value Over EBITDA-1.18
EV to Operating Cash Flow-1.28
Earnings Yield-36.12%
Free Cash Flow Yield-35.14%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Actinium Pharmaceuticals, Inc. (ATNM) on the AMEX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.343 in 2024.

What is the ticker symbol of Actinium Pharmaceuticals, Inc. stock?

The ticker symbol of Actinium Pharmaceuticals, Inc. stock is ATNM.

What is company IPO date?

IPO date of Actinium Pharmaceuticals, Inc. is 2012-12-27.

What is company current share price?

Current share price is 8.750 USD.

What is stock market cap today?

The market cap of stock today is 260605625.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 49.